Biogen Idec, Inc. (BIIB) Misses Q4 EPS by 6c; Guides FY13 EPS Below Views
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $199.71 +1.59%
Revenue Growth %: -6.5%
Financial Fact:
Total cost and expenses: 1.53B
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: -6.5%
Financial Fact:
Total cost and expenses: 1.53B
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Biogen Idec, Inc. (NASDAQ: BIIB) reported Q4 EPS of $1.40, $0.06 worse than the analyst estimate of $1.46. Revenue for the quarter came in at $1.4 billion versus the consensus estimate of $1.38 billion.
Sees FY2013 EPS of $7.15 - $7.25, versus the consensus of $7.27. Sees revs up about 10 percent.
For earnings history and earnings-related data on Biogen Idec, Inc. (BIIB) click here.
Sees FY2013 EPS of $7.15 - $7.25, versus the consensus of $7.27. Sees revs up about 10 percent.
For earnings history and earnings-related data on Biogen Idec, Inc. (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- AeroVironment restates quarterly financials, citing $89M goodwill error
- Pfizer lung cancer drug misses survival goal in Phase 3 trial
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
